featured
Pyrotinib Plus Metronomic Etoposide for Heavily Pretreated HER2-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
BMC Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study
BMC Cancer 2024 Oct 18;24(1)1290, J Liu, M He, M Jiang, S Zhou, M Zhang, Y Li, S Chen, R Cai, H Mo, B Lan, F Ma, B Xu, Q LiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.